Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

• DOI: 10.1136/jitc-2020-001556
• Publication Date: 2021-03-05T18:36:14Z
• Authors: Ravi A Madan; Fatima Karzai; Renee N Donahue; Munjid Al-Harthy; Marijo Bilusic; Inger I Rosner; Harpreet Singh; Philip M Arlen; Marc R Theoret; Jennifer L Marté; Lisa Cordes; Anna Couvillon; Amy Hankin; Moniquea Williams; Helen Owens; Sarah E Lochrin; Cindy H Chau; Seth Steinberg; William Douglas Figg; William Dahut; Jeffrey Schlom; James L Gulley
• Keywords: Enzalutamide

The standard treatment for non-metastatic castration sensitive prostate cancer (nmCSPC) is androgen deprivation therapy (ADT) or surveillance. This study evaluated the potential synergy of immunotherapy and enzalutamide (without ADT) in nmCSPC. In addition, immunologic impact was also men with normal testosterone.